 Daniel Merrick
Concepts (305)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 40 | 2023 | 2159 | 3.120 |
Why?
| | Precancerous Conditions | 10 | 2023 | 155 | 2.170 |
Why?
| | Carcinoma, Squamous Cell | 14 | 2023 | 577 | 1.910 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 13 | 2023 | 959 | 1.430 |
Why?
| | Adenocarcinoma | 7 | 2019 | 787 | 0.690 |
Why?
| | Bronchi | 6 | 2018 | 223 | 0.490 |
Why?
| | Chemoprevention | 4 | 2019 | 87 | 0.460 |
Why?
| | Biopsy | 8 | 2023 | 1024 | 0.440 |
Why?
| | Disease Progression | 7 | 2019 | 2371 | 0.430 |
Why?
| | Biomarkers, Tumor | 8 | 2018 | 1032 | 0.420 |
Why?
| | ErbB Receptors | 6 | 2023 | 554 | 0.420 |
Why?
| | Carmustine | 3 | 2020 | 47 | 0.390 |
Why?
| | Heat-Shock Proteins | 1 | 2012 | 112 | 0.380 |
Why?
| | Neovascularization, Pathologic | 5 | 2015 | 280 | 0.380 |
Why?
| | Bronchial Neoplasms | 2 | 2011 | 13 | 0.360 |
Why?
| | Papillomaviridae | 4 | 1996 | 101 | 0.350 |
Why?
| | Lung Diseases | 1 | 2015 | 690 | 0.320 |
Why?
| | Polymorphism, Genetic | 1 | 2012 | 610 | 0.320 |
Why?
| | Smoke | 3 | 2020 | 123 | 0.320 |
Why?
| | Keratinocytes | 4 | 1996 | 215 | 0.320 |
Why?
| | Proto-Oncogene Proteins | 3 | 2018 | 607 | 0.310 |
Why?
| | Smoking | 6 | 2019 | 1382 | 0.310 |
Why?
| | Inflammation | 1 | 2018 | 2464 | 0.300 |
Why?
| | Gene Dosage | 3 | 2016 | 129 | 0.290 |
Why?
| | Gene Expression Regulation, Neoplastic | 6 | 2018 | 1145 | 0.290 |
Why?
| | Carcinogenesis | 2 | 2020 | 175 | 0.290 |
Why?
| | B7-H1 Antigen | 2 | 2019 | 137 | 0.290 |
Why?
| | Epoprostenol | 2 | 2018 | 133 | 0.270 |
Why?
| | Iloprost | 4 | 2018 | 46 | 0.260 |
Why?
| | Carcinogens | 5 | 2018 | 102 | 0.260 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2023 | 307 | 0.260 |
Why?
| | Mice | 21 | 2023 | 14843 | 0.240 |
Why?
| | Mutation | 6 | 2023 | 3338 | 0.240 |
Why?
| | Humans | 49 | 2023 | 114045 | 0.240 |
Why?
| | In Situ Hybridization, Fluorescence | 3 | 2018 | 308 | 0.230 |
Why?
| | Sputum | 4 | 2019 | 286 | 0.230 |
Why?
| | Receptor, ErbB-2 | 1 | 2006 | 300 | 0.220 |
Why?
| | Immunohistochemistry | 5 | 2015 | 1624 | 0.220 |
Why?
| | Lung | 9 | 2023 | 3521 | 0.220 |
Why?
| | Cardiomyopathy, Hypertrophic, Familial | 1 | 2003 | 16 | 0.220 |
Why?
| | Neoplasm Invasiveness | 4 | 2015 | 438 | 0.210 |
Why?
| | Chest Pain | 1 | 2003 | 82 | 0.210 |
Why?
| | Cell Proliferation | 4 | 2018 | 2173 | 0.210 |
Why?
| | Desmoglein 3 | 2 | 2022 | 17 | 0.210 |
Why?
| | Epithelial-Mesenchymal Transition | 3 | 2022 | 167 | 0.200 |
Why?
| | Lidocaine | 1 | 2022 | 40 | 0.200 |
Why?
| | Gelatin | 1 | 2022 | 36 | 0.200 |
Why?
| | Female | 29 | 2022 | 59324 | 0.200 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2005 | 496 | 0.200 |
Why?
| | Middle Aged | 18 | 2020 | 26605 | 0.200 |
Why?
| | Male | 28 | 2020 | 55396 | 0.200 |
Why?
| | Neuropilin-1 | 1 | 2021 | 9 | 0.200 |
Why?
| | Ki-67 Antigen | 2 | 2015 | 102 | 0.190 |
Why?
| | Aged | 13 | 2019 | 18969 | 0.190 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 2 | 2012 | 86 | 0.180 |
Why?
| | Air Pollution | 1 | 2023 | 169 | 0.180 |
Why?
| | Disease Models, Animal | 5 | 2020 | 3498 | 0.180 |
Why?
| | Cysts | 1 | 2021 | 92 | 0.180 |
Why?
| | Receptor, IGF Type 1 | 2 | 2010 | 58 | 0.170 |
Why?
| | Animals | 21 | 2023 | 31565 | 0.170 |
Why?
| | Air Pollutants | 1 | 2023 | 244 | 0.170 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2023 | 636 | 0.170 |
Why?
| | Cell Cycle Proteins | 2 | 2018 | 549 | 0.170 |
Why?
| | Granulomatosis with Polyangiitis | 1 | 2020 | 41 | 0.170 |
Why?
| | Gene Expression Profiling | 2 | 2005 | 1518 | 0.160 |
Why?
| | Respiratory System | 1 | 2020 | 137 | 0.160 |
Why?
| | Carcinoma in Situ | 1 | 2019 | 44 | 0.160 |
Why?
| | Exons | 1 | 2020 | 301 | 0.160 |
Why?
| | gamma Catenin | 1 | 2018 | 17 | 0.150 |
Why?
| | Fluorescent Antibody Technique | 1 | 2019 | 396 | 0.150 |
Why?
| | MicroRNAs | 2 | 2016 | 600 | 0.150 |
Why?
| | Metaplasia | 1 | 2018 | 54 | 0.150 |
Why?
| | Aged, 80 and over | 7 | 2017 | 6306 | 0.150 |
Why?
| | Bronchial Diseases | 1 | 2018 | 35 | 0.150 |
Why?
| | Mucin 5AC | 1 | 2018 | 48 | 0.150 |
Why?
| | Protein Kinase Inhibitors | 3 | 2023 | 784 | 0.150 |
Why?
| | Cell Cycle Checkpoints | 1 | 2018 | 84 | 0.150 |
Why?
| | Anticarcinogenic Agents | 1 | 2018 | 66 | 0.150 |
Why?
| | Tobacco Smoke Pollution | 1 | 2020 | 217 | 0.150 |
Why?
| | RNA, Messenger | 5 | 2022 | 2550 | 0.140 |
Why?
| | Head and Neck Neoplasms | 1 | 2021 | 427 | 0.140 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2017 | 111 | 0.140 |
Why?
| | Urethane | 4 | 2023 | 41 | 0.130 |
Why?
| | Cell Transformation, Viral | 2 | 1993 | 24 | 0.130 |
Why?
| | Myocardial Infarction | 1 | 2003 | 932 | 0.130 |
Why?
| | Antigen Presentation | 1 | 2017 | 188 | 0.130 |
Why?
| | Frizzled Receptors | 1 | 2016 | 22 | 0.130 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2018 | 179 | 0.130 |
Why?
| | Adult | 11 | 2018 | 30375 | 0.130 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2016 | 67 | 0.130 |
Why?
| | Oncogenes | 1 | 2016 | 104 | 0.130 |
Why?
| | Porphyrins | 1 | 2015 | 16 | 0.130 |
Why?
| | Tomography, Spiral Computed | 1 | 2015 | 23 | 0.130 |
Why?
| | Topoisomerase Inhibitors | 1 | 2015 | 4 | 0.120 |
Why?
| | Smad4 Protein | 1 | 2015 | 34 | 0.120 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2018 | 393 | 0.120 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2019 | 333 | 0.120 |
Why?
| | Mice, Transgenic | 5 | 2018 | 1947 | 0.110 |
Why?
| | Chromosomal Instability | 1 | 2013 | 18 | 0.110 |
Why?
| | Macrophages, Alveolar | 2 | 2023 | 348 | 0.110 |
Why?
| | Stem Cells | 1 | 2018 | 541 | 0.110 |
Why?
| | Microarray Analysis | 1 | 2013 | 118 | 0.110 |
Why?
| | Neoplasms, Basal Cell | 1 | 2013 | 3 | 0.110 |
Why?
| | Endoscopy | 1 | 2015 | 245 | 0.110 |
Why?
| | Trachea | 1 | 2015 | 223 | 0.110 |
Why?
| | Prognosis | 5 | 2020 | 3315 | 0.100 |
Why?
| | Tretinoin | 1 | 1993 | 122 | 0.100 |
Why?
| | Piperidines | 2 | 2012 | 159 | 0.100 |
Why?
| | B-Lymphocytes | 1 | 2017 | 762 | 0.100 |
Why?
| | Quinazolines | 2 | 2012 | 240 | 0.100 |
Why?
| | Interleukin-1 | 1 | 1996 | 965 | 0.100 |
Why?
| | Cohort Studies | 3 | 2023 | 4883 | 0.100 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1356 | 0.100 |
Why?
| | Early Detection of Cancer | 1 | 2015 | 305 | 0.100 |
Why?
| | PTEN Phosphohydrolase | 1 | 2013 | 140 | 0.100 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2012 | 52 | 0.100 |
Why?
| | Antigens, Differentiation | 1 | 1992 | 79 | 0.100 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2017 | 959 | 0.100 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2012 | 924 | 0.090 |
Why?
| | Cell Line | 4 | 2019 | 2629 | 0.090 |
Why?
| | Hyperplasia | 1 | 2011 | 163 | 0.090 |
Why?
| | Diagnosis, Differential | 3 | 2021 | 1331 | 0.090 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 907 | 0.090 |
Why?
| | Tissue Array Analysis | 3 | 2019 | 48 | 0.090 |
Why?
| | Epithelium | 4 | 2018 | 295 | 0.090 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2012 | 224 | 0.090 |
Why?
| | Pulmonary Surgical Procedures | 1 | 2010 | 7 | 0.090 |
Why?
| | Nuclear Proteins | 3 | 2006 | 591 | 0.090 |
Why?
| | Small Cell Lung Carcinoma | 1 | 2010 | 77 | 0.080 |
Why?
| | Epithelial Cells | 4 | 2018 | 946 | 0.080 |
Why?
| | Pulmonary Alveoli | 1 | 2012 | 372 | 0.080 |
Why?
| | Follow-Up Studies | 2 | 2015 | 4392 | 0.080 |
Why?
| | Neoplasm Staging | 3 | 2020 | 1162 | 0.080 |
Why?
| | Vasodilator Agents | 1 | 2011 | 302 | 0.080 |
Why?
| | Cell Polarity | 1 | 2010 | 131 | 0.080 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2005 | 787 | 0.080 |
Why?
| | Receptors, Fibroblast Growth Factor | 1 | 2008 | 63 | 0.080 |
Why?
| | Solitary Fibrous Tumor, Pleural | 1 | 2008 | 3 | 0.080 |
Why?
| | Osteoarthropathy, Secondary Hypertrophic | 1 | 2008 | 4 | 0.080 |
Why?
| | Echocardiography | 2 | 2003 | 569 | 0.080 |
Why?
| | Smokers | 2 | 2019 | 129 | 0.070 |
Why?
| | Neoplasms, Experimental | 2 | 2018 | 149 | 0.070 |
Why?
| | Genome-Wide Association Study | 1 | 2013 | 1176 | 0.070 |
Why?
| | Fibroblast Growth Factors | 1 | 2008 | 162 | 0.070 |
Why?
| | Carcinoma, Small Cell | 1 | 2008 | 158 | 0.070 |
Why?
| | Monocytes | 1 | 2010 | 503 | 0.070 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2322 | 0.070 |
Why?
| | Edema | 1 | 2008 | 119 | 0.070 |
Why?
| | Biomarkers | 4 | 2023 | 3397 | 0.070 |
Why?
| | Radiography, Thoracic | 1 | 2008 | 150 | 0.070 |
Why?
| | Tumor Microenvironment | 2 | 2021 | 428 | 0.070 |
Why?
| | Treatment Outcome | 5 | 2022 | 9049 | 0.070 |
Why?
| | Hydrogels | 2 | 2023 | 573 | 0.070 |
Why?
| | Prevalence | 2 | 2023 | 2247 | 0.070 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 1880 | 0.070 |
Why?
| | Minichromosome Maintenance Complex Component 2 | 1 | 2006 | 4 | 0.070 |
Why?
| | Placebos | 2 | 2019 | 197 | 0.060 |
Why?
| | Hypoxia | 1 | 2012 | 956 | 0.060 |
Why?
| | Transcription Factors | 1 | 1993 | 1526 | 0.060 |
Why?
| | Mice, Inbred A | 2 | 2020 | 45 | 0.060 |
Why?
| | Chromosome Aberrations | 2 | 2017 | 134 | 0.060 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 2 | 2018 | 228 | 0.060 |
Why?
| | Prospective Studies | 4 | 2023 | 6195 | 0.060 |
Why?
| | Bronchoscopy | 2 | 2019 | 196 | 0.060 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2005 | 103 | 0.060 |
Why?
| | Japan | 1 | 2003 | 85 | 0.050 |
Why?
| | Gene Knockdown Techniques | 2 | 2015 | 301 | 0.050 |
Why?
| | Signal Transduction | 3 | 2012 | 4501 | 0.050 |
Why?
| | Aniline Compounds | 1 | 2023 | 70 | 0.050 |
Why?
| | Formaldehyde | 1 | 2022 | 46 | 0.050 |
Why?
| | Diagnostic Errors | 1 | 2003 | 150 | 0.050 |
Why?
| | Alveolar Epithelial Cells | 1 | 2023 | 93 | 0.050 |
Why?
| | Keratin-5 | 1 | 2022 | 46 | 0.050 |
Why?
| | Up-Regulation | 1 | 2005 | 802 | 0.050 |
Why?
| | Molecular Targeted Therapy | 2 | 2018 | 347 | 0.050 |
Why?
| | Particle Size | 1 | 2023 | 317 | 0.050 |
Why?
| | Mice, Inbred BALB C | 2 | 2011 | 1144 | 0.050 |
Why?
| | Sensitivity and Specificity | 1 | 2006 | 1690 | 0.050 |
Why?
| | Double-Blind Method | 2 | 2019 | 1656 | 0.050 |
Why?
| | Immunoenzyme Techniques | 2 | 2012 | 192 | 0.050 |
Why?
| | Adaptive Immunity | 1 | 2023 | 154 | 0.050 |
Why?
| | Tubulin | 1 | 2022 | 122 | 0.050 |
Why?
| | Interferon-gamma | 2 | 2018 | 719 | 0.050 |
Why?
| | Particulate Matter | 1 | 2023 | 185 | 0.050 |
Why?
| | Incidence | 2 | 2008 | 2314 | 0.050 |
Why?
| | PPAR gamma | 1 | 2022 | 182 | 0.050 |
Why?
| | Pain, Postoperative | 1 | 2022 | 190 | 0.050 |
Why?
| | Exercise Test | 1 | 2003 | 547 | 0.040 |
Why?
| | Acute Disease | 1 | 2003 | 907 | 0.040 |
Why?
| | Electrocardiography | 1 | 2003 | 561 | 0.040 |
Why?
| | Oximes | 1 | 2020 | 19 | 0.040 |
Why?
| | Breast Neoplasms | 1 | 2011 | 1846 | 0.040 |
Why?
| | Blotting, Western | 2 | 2012 | 1143 | 0.040 |
Why?
| | Environmental Exposure | 1 | 2023 | 372 | 0.040 |
Why?
| | Mice, Inbred C57BL | 2 | 2023 | 4680 | 0.040 |
Why?
| | Pyrimidinones | 1 | 2020 | 88 | 0.040 |
Why?
| | Mass Screening | 2 | 2004 | 979 | 0.040 |
Why?
| | Rituximab | 1 | 2020 | 148 | 0.040 |
Why?
| | Amino Acid Substitution | 1 | 2020 | 261 | 0.040 |
Why?
| | RNA | 1 | 2005 | 806 | 0.040 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2021 | 337 | 0.040 |
Why?
| | Pyridones | 1 | 2020 | 122 | 0.040 |
Why?
| | Imidazoles | 1 | 2020 | 203 | 0.040 |
Why?
| | Diagnostic Imaging | 1 | 2021 | 278 | 0.040 |
Why?
| | Cell Line, Transformed | 2 | 1996 | 133 | 0.040 |
Why?
| | Remission Induction | 1 | 2019 | 233 | 0.040 |
Why?
| | Risk Factors | 3 | 2019 | 8614 | 0.040 |
Why?
| | Tobacco Smoking | 1 | 2018 | 21 | 0.040 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2018 | 57 | 0.040 |
Why?
| | Tricuspid Valve | 1 | 1998 | 27 | 0.040 |
Why?
| | RNA, Small Interfering | 2 | 2012 | 534 | 0.040 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2020 | 191 | 0.040 |
Why?
| | Time | 1 | 2018 | 70 | 0.040 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2018 | 108 | 0.040 |
Why?
| | Immunotherapy | 1 | 2021 | 473 | 0.040 |
Why?
| | Ventricular Outflow Obstruction | 1 | 1998 | 38 | 0.040 |
Why?
| | Tumor Burden | 1 | 2018 | 258 | 0.040 |
Why?
| | Lymphocyte Count | 1 | 2017 | 132 | 0.040 |
Why?
| | DNA Copy Number Variations | 1 | 2018 | 153 | 0.040 |
Why?
| | Antigen-Presenting Cells | 1 | 2017 | 150 | 0.030 |
Why?
| | Carcinogenicity Tests | 1 | 1996 | 5 | 0.030 |
Why?
| | Structure-Activity Relationship | 1 | 2018 | 499 | 0.030 |
Why?
| | Blotting, Northern | 1 | 1996 | 193 | 0.030 |
Why?
| | Cells, Cultured | 2 | 2016 | 3861 | 0.030 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 1996 | 34 | 0.030 |
Why?
| | Neoplasms | 1 | 2010 | 2086 | 0.030 |
Why?
| | Immunophenotyping | 1 | 2017 | 274 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 1996 | 227 | 0.030 |
Why?
| | Centrosome | 1 | 2016 | 59 | 0.030 |
Why?
| | Plasmids | 1 | 1996 | 343 | 0.030 |
Why?
| | Cell Differentiation | 2 | 1993 | 1696 | 0.030 |
Why?
| | Smoking Cessation | 1 | 2019 | 374 | 0.030 |
Why?
| | Mitotic Index | 1 | 2015 | 26 | 0.030 |
Why?
| | Survival Analysis | 1 | 2018 | 1206 | 0.030 |
Why?
| | Mice, Nude | 1 | 1996 | 628 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2018 | 437 | 0.030 |
Why?
| | Phenotype | 2 | 1993 | 2784 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2015 | 241 | 0.030 |
Why?
| | Computational Biology | 1 | 2018 | 528 | 0.030 |
Why?
| | Uterine Cervical Neoplasms | 1 | 1996 | 213 | 0.030 |
Why?
| | Loss of Heterozygosity | 1 | 2013 | 40 | 0.030 |
Why?
| | Macrophages | 1 | 2020 | 1259 | 0.030 |
Why?
| | Cell Line, Tumor | 2 | 2012 | 2700 | 0.030 |
Why?
| | Retinoid X Receptors | 1 | 1993 | 39 | 0.030 |
Why?
| | Lymphocyte Activation | 1 | 2017 | 1036 | 0.030 |
Why?
| | DNA Repair | 1 | 2015 | 184 | 0.030 |
Why?
| | Receptors, Retinoic Acid | 1 | 1993 | 49 | 0.030 |
Why?
| | Organ Culture Techniques | 1 | 1993 | 140 | 0.030 |
Why?
| | Models, Molecular | 1 | 2018 | 1368 | 0.030 |
Why?
| | Cytosol | 1 | 1993 | 201 | 0.030 |
Why?
| | Drug Resistance | 1 | 1993 | 158 | 0.030 |
Why?
| | Respiratory Mucosa | 1 | 2015 | 251 | 0.030 |
Why?
| | United States | 2 | 2011 | 12137 | 0.030 |
Why?
| | Methylcholanthrene | 1 | 2012 | 18 | 0.030 |
Why?
| | c-Mer Tyrosine Kinase | 1 | 2012 | 43 | 0.030 |
Why?
| | Butylated Hydroxytoluene | 1 | 2012 | 31 | 0.030 |
Why?
| | Immunoprecipitation | 1 | 2012 | 151 | 0.020 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 1992 | 49 | 0.020 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 1993 | 192 | 0.020 |
Why?
| | Intermediate Filament Proteins | 1 | 1992 | 65 | 0.020 |
Why?
| | Gene Deletion | 1 | 2013 | 356 | 0.020 |
Why?
| | Administration, Topical | 1 | 2011 | 137 | 0.020 |
Why?
| | Sleep Apnea Syndromes | 1 | 2012 | 74 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2012 | 116 | 0.020 |
Why?
| | Keratins | 1 | 1992 | 176 | 0.020 |
Why?
| | Mutation, Missense | 1 | 2013 | 294 | 0.020 |
Why?
| | Antineoplastic Agents | 2 | 2012 | 1875 | 0.020 |
Why?
| | Administration, Oral | 1 | 2012 | 725 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2537 | 0.020 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2012 | 225 | 0.020 |
Why?
| | Carcinoma, Large Cell | 1 | 2010 | 14 | 0.020 |
Why?
| | RNA Interference | 1 | 2012 | 431 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2012 | 695 | 0.020 |
Why?
| | Cell Division | 1 | 1992 | 754 | 0.020 |
Why?
| | Aneuploidy | 1 | 2010 | 84 | 0.020 |
Why?
| | Mice, Inbred Strains | 1 | 2010 | 398 | 0.020 |
Why?
| | Interleukin-4 | 1 | 2010 | 204 | 0.020 |
Why?
| | Antioxidants | 1 | 2012 | 529 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2010 | 618 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2018 | 4402 | 0.020 |
Why?
| | Cell Movement | 1 | 2012 | 863 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2010 | 813 | 0.020 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2010 | 580 | 0.020 |
Why?
| | Survival Rate | 1 | 2011 | 1638 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2010 | 1078 | 0.020 |
Why?
| | Skin | 1 | 1991 | 653 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2010 | 1836 | 0.020 |
Why?
| | Databases, Nucleic Acid | 1 | 2005 | 31 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2012 | 3003 | 0.020 |
Why?
| | Enzymes | 1 | 2005 | 62 | 0.020 |
Why?
| | Cytokines | 1 | 2012 | 1824 | 0.010 |
Why?
| | Species Specificity | 1 | 2005 | 541 | 0.010 |
Why?
| | DNA Replication | 1 | 2005 | 202 | 0.010 |
Why?
| | Cluster Analysis | 1 | 2005 | 452 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2010 | 1257 | 0.010 |
Why?
| | Age Factors | 1 | 2011 | 2885 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2005 | 742 | 0.010 |
Why?
| | Apoptosis | 1 | 2012 | 2349 | 0.010 |
Why?
| | Young Adult | 1 | 2018 | 10444 | 0.010 |
Why?
| | Risk Assessment | 1 | 2010 | 2958 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2016 | 12521 | 0.010 |
Why?
| | Time Factors | 1 | 2010 | 6077 | 0.010 |
Why?
| | Echocardiography, Transesophageal | 1 | 1998 | 90 | 0.010 |
Why?
| | Culture Techniques | 1 | 1991 | 78 | 0.010 |
Why?
| | Reference Values | 1 | 1991 | 739 | 0.010 |
Why?
|
|
Merrick's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|